1
|
Guntur AR, Smith JE, Brahmandam A, DeBauche P, Cronmiller C, Lundell MJ. ZFH-2 is required for Drosophila ovarian follicle development and is expressed at the band/interband boundaries of polytene chromosomes. Dev Biol 2023; 504:1-11. [PMID: 37666353 DOI: 10.1016/j.ydbio.2023.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 08/29/2023] [Accepted: 09/01/2023] [Indexed: 09/06/2023]
Abstract
The transcription factor ZFH-2 has well-documented roles in Drosophila neurogenesis and other developmental processes. Here we provide the first evidence that ZFH-2 has a role in oogenesis. We demonstrate that ZFH-2 is expressed in the wild-type ovary and that a loss of zfh-2 function produces a mutant ovary phenotype where egg chambers are reduced in number and fused. We also show that a loss of zfh-2 function can suppress a daughterless loss-of-function ovary phenotype suggesting a possible genetic relationship between these two genes in the ovary. We also show that ZFH-2 is located at the boundary between bands and interbands on polytene chromosomes and that at a subset of these sites ZFH-2 colocalizes with the insulator/promoter cofactor CP190.
Collapse
Affiliation(s)
- Ananya R Guntur
- Department of Biology, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA
| | - John E Smith
- Department of Biology, University of Virginia, P.O. Box 400328, Charlottesville, VA, 22904, USA
| | - Archana Brahmandam
- Department of Biology, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA
| | - Phillip DeBauche
- Department of Biology, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA
| | - Claire Cronmiller
- Department of Biology, University of Virginia, P.O. Box 400328, Charlottesville, VA, 22904, USA
| | - Martha J Lundell
- Department of Biology, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA.
| |
Collapse
|
2
|
Brahmandam A, Qin J, Kim S, Jiang Y, Barajas B, Carrancio S, Peiser L. 106 Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel). J Immunother Cancer 2021. [DOI: 10.1136/jitc-2021-sitc2021.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
BackgroundLiso-cel, an autologous, CD19-directed, defined composition, 4-1BB CAR T cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells, has demonstrated efficacy and a favorable safety profile in adult patients with third-line or later large B-cell lymphoma. Clinically, disease relapse or progression may be due partly to CAR T cell exhaustion. Combination therapies promoting sustained CAR T cell pharmacologic function may increase the rate, depth, and durability of responses. CC-99282 is a novel cereblon E3 ligase modulator (CELMoD®) compound capable of co-opting cereblon to induce the recruitment and subsequent ubiquitin-mediated degradation of Ikaros/Aiolos, resulting in therapeutic effects, including enhanced antitumor activity and augmentation of T cell function.We examined CC-99282 in combination with liso-cel in acute activation and chronic stimulation assays to assess the effect of CC-99282 on liso-cel activation, exhaustion onset, and exhaustion rescue.MethodsLiso-cel produced from healthy donor T cells was subjected to acute activation (up to 72 hours) or chronic stimulation (6–7 days) to recapitulate CAR T cell exhaustion and assess effects of CC-99282 on liso-cel in a concurrent or rescue setting after CAR T cells achieved a hypofunctional exhausted state. Functional activity was measured by proliferation, cytolysis, effector cytokine production, and gene signature analyses after further culture of liso-cel with CD19+ non-Hodgkin lymphoma (NHL) cells or tumor spheroids.ResultsIn acute activation assays, CC-99282 degraded Ikaros/Aiolos in liso-cel after 24 hours and uncoupled liso-cel proliferation from cytokine production after 72 hours, demonstrated by a simultaneous increase in interferon-gamma and slowed proliferation. Concurrent incubation of liso-cel with low concentrations (nM) of CC-99282 during chronic stimulation limited liso-cel exhaustion onset with increased cytokine production and cytolysis against CD19+ NHL spheroids. Furthermore, incubation of CC-99282 with exhausted liso-cel in the rescue setting resulted in enhanced cytokine production and cytolysis compared with control. Gene expression analysis by RNA-seq confirmed that CC-99282 modulated gene signatures associated with liso-cel hypofunctionality. Interestingly, transient dosing with higher CC-99282 concentrations further alleviated T cell exhaustion, enhancing liso-cel–mediated cytolysis against CD19+ NHL cells and preserving a less differentiated CAR T cell memory phenotype.ConclusionsAt clinically relevant concentrations, CC-99282 enhanced liso-cel antitumor activity and reduced liso-cel exhaustion in in vitro CD19+ NHL models. The combination may improve efficacy of liso-cel, including response duration, in the treatment of CD19+ NHL. Additionally, CC-99282 substrate potency may support an intermittent dosing regimen for CC-99282 and liso-cel combination treatment, which could potentially improve tolerability.AcknowledgementsWe would like to thank Michael Ports for contributions to the study design and data interpretation, Shailaja Kasibhatla for contributions to the study concept and critical review, and the patients, caregivers, investigators, and study personnel. This study was funded by Bristol Myers Squibb. All authors contributed to and approved the abstract; writing and editorial assistance were provided by Allison Green, PhD, of The Lockwood Group (Stamford, CT, USA), funded by Bristol Myers Squibb.Ethics ApprovalThe authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration. Written informed consent was obtained from the healthy donor subjects.
Collapse
|
3
|
Habib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum C, Buckner JH. Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression. Diabetes 2019; 68:1240-1250. [PMID: 30894366 PMCID: PMC6610015 DOI: 10.2337/db18-1081] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Accepted: 03/15/2019] [Indexed: 01/01/2023]
Abstract
Multiple studies of B- and T-cell compartments and their response to stimuli demonstrate alterations in established type 1 diabetes (T1D). Yet it is not known whether these alterations reflect immune mechanisms that initiate islet autoimmunity, promote disease progression, or are secondary to disease. To address these questions, we used samples from the TrialNet Pathway to Prevention study to investigate T-cell responses to interleukin (IL)-2 and regulatory T cell-mediated suppression, the composition of the B-cell compartment, and B-cell responses to B-cell receptor and IL-21 receptor engagement. These studies revealed stage-dependent T- and B-cell functional and immune phenotypes; namely, early features that differentiate autoantibody-positive at-risk first-degree relatives (FDRs) from autoantibody-negative FDRs and persisted through clinical diagnosis; late features that arose at or near T1D diagnosis; and dynamic features that were enhanced early and blunted at later disease stages, indicating evolving responses along the continuum of T1D. We further explored how these specific phenotypes are influenced by therapeutic interventions. Our integrated studies provide unique insights into stable and dynamic stage-specific immune states and define novel immune phenotypes of potential clinical relevance.
Collapse
Affiliation(s)
- Tania Habib
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - S Alice Long
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Peter L Samuels
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Archana Brahmandam
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
| | - Megan Tatum
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Andrew Funk
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Anne M Hocking
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Karen Cerosaletti
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Michael T Mason
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Elizabeth Whalen
- Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, WA
| | - David J Rawlings
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
- Departments of Pediatrics and Immunology, University of Washington School of Medicine, Seattle, WA
| | - Carla Greenbaum
- Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, WA
| | - Jane H Buckner
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | | |
Collapse
|
4
|
Kolhatkar NS, Brahmandam A, Thouvenel CD, Becker-Herman S, Jacobs HM, Schwartz MA, Allenspach EJ, Khim S, Panigrahi AK, Luning Prak ET, Thrasher AJ, Notarangelo LD, Candotti F, Torgerson TR, Sanz I, Rawlings DJ. Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. ACTA ACUST UNITED AC 2015; 212:1663-77. [PMID: 26371186 PMCID: PMC4577851 DOI: 10.1084/jem.20150585] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 08/11/2015] [Indexed: 12/29/2022]
Abstract
Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency disorder frequently associated with systemic autoimmunity, including autoantibody-mediated cytopenias. WAS protein (WASp)-deficient B cells have increased B cell receptor (BCR) and Toll-like receptor (TLR) signaling, suggesting that these pathways might impact establishment of the mature, naive BCR repertoire. To directly investigate this possibility, we evaluated naive B cell specificity and composition in WASp-deficient mice and WAS subjects (n = 12). High-throughput sequencing and single-cell cloning analysis of the BCR repertoire revealed altered heavy chain usage and enrichment for low-affinity self-reactive specificities in murine marginal zone and human naive B cells. Although negative selection mechanisms including deletion, anergy, and receptor editing were relatively unperturbed, WASp-deficient transitional B cells showed enhanced proliferation in vivo mediated by antigen- and Myd88-dependent signals. Finally, using both BCR sequencing and cell surface analysis with a monoclonal antibody recognizing an intrinsically autoreactive heavy chain, we show enrichment in self-reactive cells specifically at the transitional to naive mature B cell stage in WAS subjects. Our combined data support a model wherein modest alterations in B cell-intrinsic, BCR, and TLR signals in WAS, and likely other autoimmune disorders, are sufficient to alter B cell tolerance via positive selection of self-reactive transitional B cells.
Collapse
Affiliation(s)
- Nikita S Kolhatkar
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195
| | - Archana Brahmandam
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| | - Christopher D Thouvenel
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| | - Shirly Becker-Herman
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| | - Holly M Jacobs
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| | - Marc A Schwartz
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195
| | - Eric J Allenspach
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195
| | - Socheath Khim
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| | - Anil K Panigrahi
- Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104
| | - Eline T Luning Prak
- Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104
| | - Adrian J Thrasher
- Molecular Immunology Unit, Section of Molecular and Cellular Immunology, Centre for Immunodeficiency, University College London Institute of Child Health, London WC1N 1EH, England, UK
| | | | - Fabio Candotti
- Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892
| | - Troy R Torgerson
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| | - Ignacio Sanz
- Lowance Center for Human Immunology and Division of Rheumatology, Department of Medicine, Emory University, Atlanta, GA 30322 Lowance Center for Human Immunology and Division of Rheumatology, Department of Medicine, Emory University, Atlanta, GA 30322
| | - David J Rawlings
- Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Department of Immunology and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195 Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101
| |
Collapse
|
5
|
Meyer-Bahlburg A, Renner ED, Rylaarsdam S, Reichenbach J, Schimke LF, Marks A, Tcheurekdjian H, Hostoffer R, Brahmandam A, Torgerson TR, Belohradsky BH, Rawlings DJ, Ochs HD. Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation. J Allergy Clin Immunol 2012; 129:559-62, 562.e1-2. [DOI: 10.1016/j.jaci.2011.09.017] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2011] [Revised: 08/27/2011] [Accepted: 09/08/2011] [Indexed: 11/28/2022]
|
6
|
Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum C, Rawlings DJ, Buckner JH. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 2011; 188:487-96. [PMID: 22105996 DOI: 10.4049/jimmunol.1102176] [Citation(s) in RCA: 104] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The PTPN22 genetic variant 1858T, encoding Lyp620W, is associated with multiple autoimmune disorders for which the production of autoantibodies is a common feature, suggesting a loss of B cell tolerance. Lyp620W results in blunted BCR signaling in memory B cells. Because BCR signal strength is tightly coupled to central and peripheral tolerance, we examined whether Lyp620W impacts peripheral B cell homeostasis in healthy individuals heterozygous for the PTPN221858T variant. We found that these subjects display alterations in the composition of the B cell pool that include specific expansion of the transitional and anergic IgD(+)IgM(-)CD27(-) B cell subsets. The PTPN22 1858T variant was further associated with significantly diminished BCR signaling and a resistance to apoptosis in both transitional and naive B cells. Strikingly, parallel changes in both BCR signaling and composition of B cell compartment were observed in type 1 diabetic subjects, irrespective of PTPN22 genotype, revealing a novel immune phenotype and likely shared mechanisms leading to a loss of B cell tolerance. Our combined findings suggest that Lyp620W-mediated effects, due in part to the altered BCR signaling threshold, contribute to breakdown of peripheral tolerance and the entry of autoreactive B cells into the naive B cell compartment.
Collapse
Affiliation(s)
- Tania Habib
- Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Muzzafar T, Medeiros LJ, Wang SA, Brahmandam A, Thomas DA, Jorgensen JL. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol 2009; 132:692-8. [PMID: 19846809 DOI: 10.1309/ajcp02rpvoktnwec] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
We studied CD81 expression by flow cytometry (FC) on benign precursor B cells (hematogones) and leukemic blasts in precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) and established its usefulness in minimal residual disease (MRD) assays. Hematogones showed uniformly bright CD81 expression. In 98 pre-B-ALLs at diagnosis or overt relapse, 80 (82%) showed aberrantly decreased CD81 intensity. We used hematogones in 139 MRD- specimens to set a lower threshold for normal CD81 expression. In 133 specimens positive for residual pre-B-ALL, 87.2% showed increased CD81-dim immature B cells (>10%) and/or a discrete cluster of CD81-dim cells in a background of hematogones. Only 1 of 139 MRD- specimens showed more than 10% CD81-dim cells. Decreased CD81 expression was maintained in 91% of aberrant cases analyzed before and after chemotherapy. Decreased CD81 expression is a sensitive and specific marker for residual pre-B-ALL, even in a background of hematogones, making CD81 a useful addition to a panel for MRD detection by FC.
Collapse
|
8
|
Han X, Jorgensen JL, Brahmandam A, Schlette E, Huh YO, Shi Y, Awagu S, Chen W. Immunophenotypic study of basophils by multiparameter flow cytometry. Arch Pathol Lab Med 2008; 132:813-9. [PMID: 18466030 DOI: 10.5858/2008-132-813-isobbm] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2007] [Indexed: 11/06/2022]
Abstract
CONTEXT The immunophenotypic profile of basophils is not yet fully established, and the immunophenotypic changes in chronic myelogenous leukemia are not fully characterized. OBJECTIVE To establish a comprehensive immunophenotypic spectrum of normal basophils and to assess the range of immunophenotypic aberrations of basophils in chronic myelogenous leukemia. DESIGN Using 4-color flow cytometry, we compared the immunophenotypic profile of basophils in peripheral blood or bone marrow samples from 20 patients with no evidence of neoplasia to basophils from 15 patients with chronic myelogenous leukemia. RESULTS Basophils in control cases were all positive for CD9, CD13, CD22, CD25 (dim), CD33, CD36, CD38 (bright), CD45 (dimmer than lymphocytes and brighter than myeloblasts), and CD123 (bright), and were negative for CD19, CD34, CD64, CD117, and HLA-DR. Basophils in all chronic myelogenous leukemia patients possessed 1 to 5 immunophenotypic aberrancies. The most common aberrancies were underexpression of CD38, followed by aberrant expression of CD64 and underexpression of CD123. CD34 and CD117 were present in cases with basophilic precursors. Myeloblasts showed a distinct immunophenotypic profile, as they typically expressed CD34 and CD117, showed dimmer expression (compared with basophils) of CD38, CD45, and CD123, and lacked expression of CD22. CONCLUSIONS Flow cytometric immunophenotyping can identify immunophenotypic aberrations of basophils in chronic myelogenous leukemia, and discriminate basophils from myeloblasts.
Collapse
Affiliation(s)
- Xiaohong Han
- Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | | | |
Collapse
|